Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 8/20 | 0.43 |
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 2/20 | 0.40 |
| ▸ | ATG4B | Q9Y4P1 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4231895 | 0.94 | CASR (0.43) | CASRATRMEN1KMT2AKDM4E | |
| SCHEMBL481313 | 0.77 | ATR (0.43) | ATRKDM4EALDH1A1 | |
| SCHEMBL481621 | 0.73 | MTOR (0.58) | ATRKMT2AKDM4EMAPTHKDC1 | |
| SCHEMBL1522822 | 0.72 | LMNA (0.50) | CASRMEN1KMT2AKDM4EMAPT | |
| SCHEMBL481544 | 0.68 | MET (0.40) | ATRKDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL481546 | 0.68 | MET (0.40) | ATRKDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL481637 | 0.67 | MAP3K11 (0.51) | ATRALDH1A1TSHR | |
| SCHEMBL2504653 | 0.65 | MTOR (0.48) | — | |
| SCHEMBL3955508 | 0.65 | ATR (0.49) | ATRKMT2ALMNAMAPK1 | |
| SCHEMBL481361 | 0.65 | MTOR (0.61) | KDM4EMAPTLMNAGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2961408-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2016-01-06 | — | — | EP | disclosed |
| EP-2908814-A2 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2015-08-26 | — | — | EP | disclosed |
| EP-2909627-A2 | INHIBITION OF PHOSPHORYLATION OF PRAS40, GSK3-BETA OR P70S6K1 AS A MARKER FOR TOR KINASE INHIBITORY ACTIVITY | Signal Pharmaceuticals, LLC (US) | 2015-08-26 | — | — | EP | disclosed |
| EP-2825170-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2015-01-21 | — | — | EP | disclosed |
| EP-2825171-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2015-01-21 | — | — | EP | disclosed |
| EP-2825169-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2015-01-21 | — | — | EP | disclosed |
| EP-2825168-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2015-01-21 | — | — | EP | disclosed |
| EP-2817029-A1 | METHODS FOR TREATING NON- SMALL CELL LUNG CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | Signal Pharmaceuticals, LLC (US) | 2014-12-31 | — | — | EP | disclosed |
| WO-2014062878-A9 | TREATMENT OF PROSTATE CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014134240-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2014-09-04 | — | — | WO | disclosed |
| WO-2013138560-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | WO | disclosed |
| WO-2013138556-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | WO | disclosed |
| WO-2013138553-A1 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-09-19 | — | — | WO | disclosed |
| WO-2013126636-A1 | METHODS FOR TREATING NON- SMALL CELL LUNG CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-08-29 | — | — | WO | disclosed |
| WO-2013059396-A2 | TREATMENT OF CANCER WITH TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2013019927-A1 | IDENTIFICATION OF GENE EXPRESSION PROFILE AS A PREDICTIVE BIOMARKER FOR LKB1 STATUS | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-02-07 | — | — | WO | disclosed |
| EP-2531194-A1 | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | Signal Pharmaceuticals, LLC (US) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011097333-A1 | IDENTIFICATION OF LKB1 MUTATION AS A PREDICTIVE BIOMARKER FOR SENSITIVITY TO TOR KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-08-11 | — | — | WO | disclosed |
| EP-2078016-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals LLC (US) | 2009-07-15 | — | — | EP | disclosed |
| WO-2008051493-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-05-02 | — | — | WO | disclosed |